These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11230300)

  • 1. The future of hypertension therapy: sense, antisense, or nonsense?
    Pachori AS; Huentelman MJ; Francis SC; Gelband CH; Katovich MJ; Raizada MK
    Hypertension; 2001 Feb; 37(2 Pt 2):357-64. PubMed ID: 11230300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of antisense DNA by vectors for prolonged effects in vitro and in vivo.
    Mohuczy D; Tang X; Phillips MI
    Methods Enzymol; 2000; 314():32-51. PubMed ID: 10565003
    [No Abstract]   [Full Text] [Related]  

  • 3. Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA.
    Reaves PY; Wang HW; Katovich MJ; Gelband CH; Raizada MK
    Methods; 2000 Nov; 22(3):211-8. PubMed ID: 11071816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic targeting of the renin-angiotensin system for long-term control of hypertension.
    Metcalfe BL; Raizada M; Katovich MJ
    Curr Hypertens Rep; 2002 Feb; 4(1):25-31. PubMed ID: 11790288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy.
    Pachori AS; Numan MT; Ferrario CM; Diz DM; Raizada MK; Katovich MJ
    Hypertension; 2002 May; 39(5):969-75. PubMed ID: 12019278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension.
    Gelband CH; Reaves PY; Evans J; Wang H; Katovich MJ; Raizada MK
    Hypertension; 1999 Jan; 33(1 Pt 2):360-5. PubMed ID: 9931130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.
    Phillips MI
    Am J Cardiol; 1998 Nov; 82(10A):60S-62S. PubMed ID: 9860363
    [No Abstract]   [Full Text] [Related]  

  • 9. Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring.
    Reaves PY; Gelband CH; Wang H; Yang H; Lu D; Berecek KH; Katovich MJ; Raizada MK
    Circ Res; 1999 Nov; 85(10):e44-50. PubMed ID: 10559146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.
    Martens JR; Reaves PY; Lu D; Katovich MJ; Berecek KH; Bishop SP; Raizada MK; Gelband CH
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2664-9. PubMed ID: 9482944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirally mediated delivery of angiotensin II type 1 receptor antisense in vitro and in vivo.
    Wang H; Lu D; Reaves PY; Katovich MJ; Raizada MK
    Methods Enzymol; 2000; 314():581-90. PubMed ID: 10565039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR.
    Wang H; Reaves PY; Gardon ML; Keene K; Goldberg DS; Gelband CH; Katovich MJ; Raizada MK
    Hypertension; 2000 Jan; 35(1 Pt 2):202-8. PubMed ID: 10642298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy to control hypertension: current studies and future perspectives.
    Sellers KW; Katovich MJ; Gelband CH; Raizada MK
    Am J Med Sci; 2001 Jul; 322(1):1-6. PubMed ID: 11465240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of ANG II actions by adenovirus delivery of AT1 receptor antisense in neurons and SMC.
    Lu D; Yang H; Raizada MK
    Am J Physiol; 1998 Feb; 274(2):H719-27. PubMed ID: 9486279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.
    Phillips MI; Mohuczy-Dominiak D; Coffey M; Galli SM; Kimura B; Wu P; Zelles T
    Hypertension; 1997 Jan; 29(1 Pt 2):374-80. PubMed ID: 9039130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of the renin-angiotensin system by antisense gene therapy: a possible strategy for the long-term control of hypertension.
    Raizada MK; Francis SC; Wang H; Gelband CH; Reaves PY; Katovich MJ
    J Hypertens; 2000 Apr; 18(4):353-62. PubMed ID: 10779083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for hypertension: antisense inhibition of the renin-angiotensin system.
    Phillips MI; Kimura B
    Methods Mol Med; 2005; 108():363-79. PubMed ID: 16028695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR.
    Katovich MJ; Gelband CH; Reaves P; Wang HW; Raizada MK
    Am J Physiol; 1999 Sep; 277(3):H1260-4. PubMed ID: 10484448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged attenuation of cold-induced hypertension by adenoviral delivery of renin antisense.
    Wang X; Sun Z; Cade R
    Kidney Int; 2005 Aug; 68(2):680-7. PubMed ID: 16014045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense.
    Iyer SN; Lu D; Katovich MJ; Raizada MK
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9960-5. PubMed ID: 8790439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.